$CURR Gross revenue of $1.6 million had an increas
Post# of 41828
![Avatar](/images/ProfileImages/no_avatar_available.jpg)
*CURR drastically decreased their SG&A expenses by $3.4 million in the first half of 2022. The recent cost reductions and operating leverage helped narrow their operating loss by $1.0 million in 2022.
Quote from the CEO on their impressive quarter:
Quote:
"We are seeing positive results from our new marketing initiatives with increasing sales trends in the first six weeks of Q3 as we work to increase our revenues significantly in the second half and should see an additional acceleration in Q4. During Q2 we worked on successfully increasing our gross margins, while we continually work to decrease the SG&A."
https://finance.yahoo.com/news/cure-pharmaceu...00381.html
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.